Rigel Pharmaceuticals Inc

2026-08-25 20:07; UTC

Rigel Pharmaceuticals shares are advancing, supported by easing Treasury yields and lower oil prices, despite pulling back from earlier session highs.

2026-08-24 19:56; UTC

Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026-08-21 19:36; UTC

Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.

2026-08-20 20:06; UTC

Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.

2026-08-19 20:02; UTC

Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.

2026-08-18 22:01; UTC

Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.

2026-08-17 20:06; UTC

Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.

2026-08-14 20:06; UTC

HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.

2026-08-13 19:16; UTC

Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.

2026-08-11 20:06; UTC

Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.

2026-08-07 19:26; UTC

Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.

2026-08-06 20:06; UTC

Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.

2026-08-05 20:02; UTC

Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.

2026-08-04 23:01; UTC

Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.

2026-08-03 19:26; UTC

Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.

2026-07-31 19:41; UTC

Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.

2026-07-30 19:29; UTC

Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.

2026-07-29 19:47; UTC

Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.

2026-07-28 19:56; UTC

Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.

2026-07-27 16:16; UTC

Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.

2026-07-24 20:01; UTC

Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.

2026-07-22 20:06; UTC

Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.

2026-07-21 17:26; UTC

Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.